Innovating antibodies, improving lives
Genmab reported its 2019 Full Year financial results on February 19 and held an investor conference call to discuss the results. Click here to listen to a replay of the webcast call; here to download the full Annual Report; here to download a Danish Summary of the Annual Report; here for an online summary of the report and; here to download the conference call slides.
Genmab is seeking new employees to join our team. Visit our Careers webpages to explore current vacancies, learn about our culture and meet some of our team members. Click here to visit Genmab's page on LinkedIn.
To register your email address for electronic shareholder communication or to update your settings, log on to the InvestorPortal.
Genmab Publishes 2019 Annual Report
Horizon Therapeutics Secures U.S. FDA Approval for Teprotumumab, for the Treatment of Thyroid Eye Disease (TED)
Genmab Announces 2019 Net Sales Figures for DARZALEX® (daratumumab) and Achievement of USD 150 Million Sales Milestone in DARZALEX Collaboration with Janssen
Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
More Genmab News Releases